BACKGROUND: Staphylococcus aureus causes serious infections in both hospital and community settings. Attempts have been made to prevent human infection through vaccination against bacterial cell-surface antigens; thus far all have failed. Here we show that superantigens and cytolysins, when used in vaccine cocktails, provide protection from S. aureus USA100-USA400 intrapulmonary challenge. METHODS: Rabbits were actively vaccinated (wild-type toxins or toxoids) or passively immunized (hyperimmune serum) against combinations of superantigens (toxic shock syndrome toxin 1, enterotoxins B and C, and enterotoxin-like X) and cytolysins (α-, β-, and γ-toxins) and challenged intrapulmonarily with multiple strains of S. aureus, both methicillin-sensitive and methicillin-resistant. RESULTS: Active vaccination against a cocktail containing bacterial cell-surface antigens enhanced disease severity as tested by infective endocarditis. Active vaccination against secreted superantigens and cytolysins resulted in protection of 86 of 88 rabbits when challenged intrapulmonarily with 9 different S. aureus strains, compared to only 1 of 88 nonvaccinated animals. Passive immunization studies demonstrated that production of neutralizing antibodies was an important mechanism of protection. CONCLUSIONS: The data suggest that vaccination against bacterial cell-surface antigens increases disease severity, but vaccination against secreted virulence factors provides protection against S. aureus. These results advance our understanding of S. aureus pathogenesis and have important implications in disease prevention.
BACKGROUND:Staphylococcus aureus causes serious infections in both hospital and community settings. Attempts have been made to prevent human infection through vaccination against bacterial cell-surface antigens; thus far all have failed. Here we show that superantigens and cytolysins, when used in vaccine cocktails, provide protection from S. aureus USA100-USA400 intrapulmonary challenge. METHODS:Rabbits were actively vaccinated (wild-type toxins or toxoids) or passively immunized (hyperimmune serum) against combinations of superantigens (toxic shock syndrome toxin 1, enterotoxins B and C, and enterotoxin-like X) and cytolysins (α-, β-, and γ-toxins) and challenged intrapulmonarily with multiple strains of S. aureus, both methicillin-sensitive and methicillin-resistant. RESULTS: Active vaccination against a cocktail containing bacterial cell-surface antigens enhanced disease severity as tested by infective endocarditis. Active vaccination against secreted superantigens and cytolysins resulted in protection of 86 of 88 rabbits when challenged intrapulmonarily with 9 different S. aureus strains, compared to only 1 of 88 nonvaccinated animals. Passive immunization studies demonstrated that production of neutralizing antibodies was an important mechanism of protection. CONCLUSIONS: The data suggest that vaccination against bacterial cell-surface antigens increases disease severity, but vaccination against secreted virulence factors provides protection against S. aureus. These results advance our understanding of S. aureus pathogenesis and have important implications in disease prevention.
Authors: John S Francis; Meg C Doherty; Uri Lopatin; Cecilia P Johnston; Gita Sinha; Tracy Ross; Mian Cai; Nadia N Hansel; Trish Perl; John R Ticehurst; Karen Carroll; David L Thomas; Eric Nuermberger; John G Bartlett Journal: Clin Infect Dis Date: 2004-12-07 Impact factor: 9.079
Authors: Kristi L Strandberg; Jessica H Rotschafer; Sara M Vetter; Rebecca A Buonpane; David M Kranz; Patrick M Schlievert Journal: J Infect Dis Date: 2010-10-27 Impact factor: 5.226
Authors: Christopher Burlak; Carl H Hammer; Mary-Ann Robinson; Adeline R Whitney; Martin J McGavin; Barry N Kreiswirth; Frank R Deleo Journal: Cell Microbiol Date: 2007-01-09 Impact factor: 3.715
Authors: Ying-Chi Lin; Michele J Anderson; Petra L Kohler; Kristi L Strandberg; Michael E Olson; Alexander R Horswill; Patrick M Schlievert; Marnie L Peterson Journal: Biochemistry Date: 2011-07-21 Impact factor: 3.162
Authors: Olivia N Chuang; Patrick M Schlievert; Carol L Wells; Dawn A Manias; Timothy J Tripp; Gary M Dunny Journal: Infect Immun Date: 2008-10-27 Impact factor: 3.441
Authors: Patrick M Schlievert; Olivia N Chuang-Smith; Marnie L Peterson; Laura C C Cook; Gary M Dunny Journal: PLoS One Date: 2010-10-04 Impact factor: 3.240
Authors: Aristides P Assimacopoulos; Kristi L Strandberg; Jessica H Rotschafer; Patrick M Schlievert Journal: Clin Infect Dis Date: 2009-03-01 Impact factor: 9.079
Authors: Batu K Sharma-Kuinkel; Yuling Wu; David E Tabor; Hoyin Mok; Bret R Sellman; Amy Jenkins; Li Yu; Hasan S Jafri; Thomas H Rude; Felicia Ruffin; Wiley A Schell; Lawrence P Park; Qin Yan; Joshua T Thaden; Julia A Messina; Vance G Fowler; Mark T Esser Journal: J Clin Microbiol Date: 2014-11-12 Impact factor: 5.948
Authors: Melissa J Karau; Mulualem E Tilahun; Ashton Krogman; Barbara A Osborne; Richard A Goldsby; Chella S David; Jayawant N Mandrekar; Robin Patel; Govindarajan Rajagopalan Journal: Virulence Date: 2016-12-07 Impact factor: 5.882
Authors: Koneni V Sashidhara; K Bhaskara Rao; Pragati Kushwaha; Ram K Modukuri; Pratiksha Singh; Isha Soni; P K Shukla; Sidharth Chopra; Mukesh Pasupuleti Journal: ACS Med Chem Lett Date: 2015-05-29 Impact factor: 4.345
Authors: Joseph A Merriman; Aloysius J Klingelhutz; Daniel J Diekema; Donald Y M Leung; Patrick M Schlievert Journal: Biochemistry Date: 2015-07-28 Impact factor: 3.162